BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 30381375)

  • 1. Nrf2 regulates CD4
    Tsai JJ; Velardi E; Shono Y; Argyropoulos KV; Holland AM; Smith OM; Yim NL; Rao UK; Kreines FM; Lieberman SR; Young LF; Lazrak A; Youssef S; Fu YY; Liu C; Lezcano C; Murphy GF; Na IK; Jenq RR; Hanash AM; Dudakov JA; van den Brink MRM
    Blood; 2018 Dec; 132(26):2763-2774. PubMed ID: 30381375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STING negatively regulates allogeneic T-cell responses by constraining antigen-presenting cell function.
    Wu Y; Tang CA; Mealer C; Bastian D; Hanief Sofi M; Tian L; Schutt S; Choi HJ; Ticer T; Zhang M; Sui X; Huang L; Mellor AL; Hu CA; Yu XZ
    Cell Mol Immunol; 2021 Mar; 18(3):632-643. PubMed ID: 33500563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell-specific notch inhibition blocks graft-versus-host disease by inducing a hyporesponsive program in alloreactive CD4+ and CD8+ T cells.
    Sandy AR; Chung J; Toubai T; Shan GT; Tran IT; Friedman A; Blackwell TS; Reddy P; King PD; Maillard I
    J Immunol; 2013 Jun; 190(11):5818-28. PubMed ID: 23636056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells.
    Wu T; Young JS; Johnston H; Ni X; Deng R; Racine J; Wang M; Wang A; Todorov I; Wang J; Zeng D
    J Immunol; 2013 Jul; 191(1):488-99. PubMed ID: 23709681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse nidovirus LDV infection alleviates graft versus host disease and induces type I IFN-dependent inhibition of dendritic cells and allo-responsive T cells.
    Gaignage M; Marillier RG; Uyttenhove C; Dauguet N; Saxena A; Ryffel B; Michiels T; Coutelier JP; Van Snick J
    Immun Inflamm Dis; 2017 Jun; 5(2):200-213. PubMed ID: 28474504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a coordinated CD8 and CD4 T cell response directed against mismatched HLA Class I causing severe acute graft-versus-host disease.
    Amir AL; Hagedoorn RS; van Luxemburg-Heijs SA; Marijt EW; Kruisselbrink AB; Frederik Falkenburg JH; Heemskerk MH
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):210-9. PubMed ID: 22015995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
    Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
    PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 serves as a double agent in separating GVL from GVHD.
    Brennan TV; Yang Y
    J Clin Invest; 2017 May; 127(5):1627-1630. PubMed ID: 28414300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity.
    Vaeth M; Bäuerlein CA; Pusch T; Findeis J; Chopra M; Mottok A; Rosenwald A; Beilhack A; Berberich-Siebelt F
    Proc Natl Acad Sci U S A; 2015 Jan; 112(4):1125-30. PubMed ID: 25583478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An essential role for IFN-gamma in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation.
    Asavaroengchai W; Wang H; Wang S; Wang L; Bronson R; Sykes M; Yang YG
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):46-55. PubMed ID: 17222752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. During acute graft versus host disease CD28 deletion in donor CD8
    Uri A; Lühder F; Kerkau T; Beyersdorf N
    Eur J Immunol; 2018 Dec; 48(12):2055-2067. PubMed ID: 30320878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease.
    Kato K; Cui S; Kuick R; Mineishi S; Hexner E; Ferrara JL; Emerson SG; Zhang Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):751-71. PubMed ID: 20116439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation.
    Hashimoto D; Chow A; Greter M; Saenger Y; Kwan WH; Leboeuf M; Ginhoux F; Ochando JC; Kunisaki Y; van Rooijen N; Liu C; Teshima T; Heeger PS; Stanley ER; Frenette PS; Merad M
    J Exp Med; 2011 May; 208(5):1069-82. PubMed ID: 21536742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T memory stem cells after allogeneic haematopoietic cell transplantation: unique long-term kinetics and influence of chronic graft-versus-host disease.
    Jimbo K; Konuma T; Watanabe E; Kohara C; Mizukami M; Nagai E; Oiwa-Monna M; Mizusawa M; Isobe M; Kato S; Takahashi S; Tojo A
    Br J Haematol; 2019 Sep; 186(6):866-878. PubMed ID: 31135974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteopontin attenuates acute gastrointestinal graft-versus-host disease by preventing apoptosis of intestinal epithelial cells.
    Kawakami K; Minami N; Matsuura M; Iida T; Toyonaga T; Nagaishi K; Arimura Y; Fujimiya M; Uede T; Nakase H
    Biochem Biophys Res Commun; 2017 Apr; 485(2):468-475. PubMed ID: 28192120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of allogeneic CD8+ T-cell response by DZNep controls GVHD while preserving hematopoietic chimerism.
    Wang J; Li L; Xu M; Rong R; Zhu T
    Transplantation; 2013 Nov; 96(9):774-81. PubMed ID: 23900211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.
    Hossain MS; Kunter GM; El-Najjar VF; Jaye DL; Al-Kadhimi Z; Taofeek OK; Li JM; Waller EK
    PLoS One; 2017; 12(9):e0184254. PubMed ID: 28953925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality.
    Thangavelu G; Lee YC; Loschi M; Schaechter KM; Feser CJ; Koehn BH; Nowak EC; Zeiser R; Serody JS; Murphy WJ; Munn DH; Chambon P; Noelle RJ; Blazar BR
    J Immunol; 2019 May; 202(9):2795-2805. PubMed ID: 30885956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice.
    Wu Y; Heinrichs J; Bastian D; Fu J; Nguyen H; Schutt S; Liu Y; Jin J; Liu C; Li QJ; Xia C; Yu XZ
    Blood; 2015 Sep; 126(11):1314-23. PubMed ID: 26138686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.